Kedrion Biopharma is a biopharmaceutical company that collects and fractionates blood plasma to produce and distribute worldwide plasma-derived therapies for use in treating and preventing rare and serious diseases and conditions.
In 2022, Kedrion joined forces with BPL (Bio Products Laboratory). Based in the United Kingdom, BPL has over 60 years of experience in the supply of high-quality plasma-derived medicines to treat rare diseases.
Kedrion distributes its products in over 100 countries and is the world’s 5th top player in the field of plasma-derived products.
Kedrion Results for the quarter ended March 31, 2023
Announcement of delisting of Kedrion SpA (the “Issuer”)
Notice of confirmation of redemption condition of Kedrion SpA (the “Issuer”)
KEDRION CONSOLIDATED FINANCIAL STATEMENT AS OF MARCH 31, 2023
KEVLAR CONSOLIDATED FINANCIAL STATEMENTS AS OF MARCH 31, 2023
CONSOLIDATED FINANCIAL STATEMENTS AS AT DECEMBER 31, 2022
CONSOLIDATED FINANCIAL STATEMENTS Q1 2022
CONSOLIDATED FINANCIAL STATEMENTS AS AT DECEMBER 31, 2021
CONSOLIDATED FINANCIAL STATEMENTS AS AT SEPTEMBER 30, 2021
CONSOLIDATED FIRST HALF RESULTS 2021
CONSOLIDATED FINANCIAL STATEMENTS Q1 2021
CONSOLIDATED FINANCIAL STATEMENTS 2020
CONSOLIDATED FIRST HALF RESULTS 2020
CONTACT & EMAIL ALERTS
Subscribe to the service in order to receive our news